Skip to main content

Table 1 Outcome assessments completed at baseline assessment, end of treatment period 1, after washout (baseline 2), and end of treatment period 2

From: Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)

Primary outcome measure:

 • Neuropsychiatry Inventory (NPI) apathy/indifference domain score [42]

Secondary outcome measures:

 • Interpersonal Reactivity Index (IRI) empathic concern scale and total score [33]

 • Clinician’s Global Impression of Change (apathy) (m-CGIC) scores [43, 44]

 • Emotional facial expression recognition performance [17]

 • Revised Self-Monitoring Scale (RSMS) score [45]

 • NPI caregiver distress scores on NPI apathy/indifference scale and total caregiver distress scores [42]

 • Total NPI scores

 • Cambridge Behavioural Inventory [46]

 • Addenbrooke’s Cognitive Examination III [47]

 • Social Observation Checklist blinded central ratings of videotaped meals with patients and caregivers [35].